Forefront Analytics’s Codiak BioSciences CDAK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
– Sell
-110,210
Closed -$19.2K – 80
2023
Q1
$19.2K Buy
110,210
+10,275
+10% +$5.72K 0.01% 79
2022
Q4
$39.7K Buy
99,935
+43,450
+77% +$28.6K 0.02% 70
2022
Q3
$47K Buy
56,485
+38,175
+208% +$80.1K 0.03% 64
2022
Q2
$57K Sell
18,310
-1,000
-5% -$3.51K 0.03% 63
2022
Q1
$122K Buy
+19,310
New +$121K 0.05% 57

Forefront Analytics's CDAK Position: Q2 2023 in Review

Forefront Analytics sold out of Codiak BioSciences (CDAK) in Q2 2023, closing a stake of 110,210 shares — an estimated $19.2K sold.

Forefront Analytics first reported a position in CDAK in Q1 2022 and held it in 5 quarters. The position peaked at $122K in Q1 2022. 1 fund tracked by Wall St. Rank holds CDAK as of Q2 2023.

  • Forefront Analytics reported no remaining Codiak BioSciences position as of Q2 2023 after selling out during the quarter.
  • Forefront Analytics sold 110,210 Codiak BioSciences shares in Q2 2023, an estimated $19.2K.
  • Forefront Analytics first reported a position in Codiak BioSciences in Q1 2022 and held it in 5 quarters.
  • Forefront Analytics's Codiak BioSciences position peaked at $122K in Q1 2022.
  • 1 fund tracked by Wall St. Rank held Codiak BioSciences as of Q2 2023.

Based on Forefront Analytics's 13F filing for Q2 2023, filed 11 Aug 2023.